Harvest Fund Management Co. Ltd Acquires 1,561 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Harvest Fund Management Co. Ltd increased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 24.4% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 7,954 shares of the biopharmaceutical company’s stock after buying an additional 1,561 shares during the period. Harvest Fund Management Co. Ltd’s holdings in Regeneron Pharmaceuticals were worth $6,139,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of the business. Vanguard Group Inc. raised its stake in Regeneron Pharmaceuticals by 0.3% in the fourth quarter. Vanguard Group Inc. now owns 9,075,153 shares of the biopharmaceutical company’s stock worth $7,004,838,000 after buying an additional 26,884 shares in the last quarter. Dodge & Cox raised its stake in Regeneron Pharmaceuticals by 18.9% in the third quarter. Dodge & Cox now owns 4,550,845 shares of the biopharmaceutical company’s stock worth $2,558,804,000 after buying an additional 724,562 shares in the last quarter. Franklin Resources Inc. raised its stake in Regeneron Pharmaceuticals by 6.0% in the third quarter. Franklin Resources Inc. now owns 2,453,143 shares of the biopharmaceutical company’s stock worth $1,379,329,000 after buying an additional 139,647 shares in the last quarter. Capital World Investors raised its stake in Regeneron Pharmaceuticals by 1.6% in the third quarter. Capital World Investors now owns 1,998,366 shares of the biopharmaceutical company’s stock worth $1,123,609,000 after buying an additional 32,348 shares in the last quarter. Finally, Invesco Ltd. raised its stake in Regeneron Pharmaceuticals by 38.0% in the third quarter. Invesco Ltd. now owns 1,484,473 shares of the biopharmaceutical company’s stock worth $834,675,000 after buying an additional 408,649 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $628.73 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96. The stock’s fifty day moving average price is $709.21 and its 200 day moving average price is $742.91. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $821.11. The company has a market cap of $66.47 billion, a price-to-earnings ratio of 15.32, a PEG ratio of 1.37 and a beta of 0.25.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The firm had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.48 billion. During the same period in the prior year, the firm earned $8.22 EPS. The firm’s revenue was up 19.0% on a year-over-year basis. As a group, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.25 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were given a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.16%.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron expanded its strategic cancer partnership with CytomX to develop conditionally activated bispecific therapeutics, adding two new programs and optionality for more targets, which strengthens the company’s oncology pipeline and long-term growth prospects. REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics
• Positive Sentiment: Regeneron also said it will highlight new clinical data and research from its metabolic disease, ophthalmology, and rare disease pipelines at upcoming ADA and ENDO meetings, reinforcing investor focus on multiple potential catalysts beyond oncology. Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
• Neutral Sentiment: Analyst and market commentary pointed to the expanded oncology collaboration and positive clinical trial updates as the reasons REGN shares moved higher, suggesting sentiment is being driven by pipeline optionality and business-development momentum. Why Regeneron (REGN) Stock Is Trading Up Today
• Negative Sentiment: Pomerantz LLP said it is investigating claims on behalf of Regeneron investors, which could create headline risk, though the notice did not include any findings or financial impact. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. – REGN

Insider Activity

In related news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $705.24, for a total value of $70,524.00. Following the transaction, the director directly owned 17,503 shares of the company’s stock, valued at $12,343,815.72. This represents a 0.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of brokerages recently commented on REGN. Wall Street Zen raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. JPMorgan Chase & Co. reduced their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating for the company in a research note on Monday, May 18th. Zacks Research downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 6th. Barclays reduced their price target on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating on the stock in a research report on Thursday, April 30th. Finally, BMO Capital Markets reduced their price target on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating on the stock in a research report on Monday, May 18th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $792.65.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.